A TElmisartan and AMlodipine STudy to Assess the cardiovascular PROTECTive effects as measured by endothelial dysfunction in hypertensive at risk patients beyond blood pressure - TEAMSTA PROTECT I

niversitätsmedizin der Johannes Gutenberg-Universität Mainz0 个研究点开始时间: 2010年4月1日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•?Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation.
•?Age 35 years or older.
•?Male and female, treated and treatment-naive patients with uncontrolled hypertension (defined as 20/10 mmHg above target BP of <140/90 mmHg [<130/80 mmHg for renally impaired and/ or diabetics patients])
•?Male and female treated patients with controlled hypertension (defined as target BP < 140/90 mmHg [ < 130/80 mmHg for renally impaired and/ or diabetics patients])
•?> 3 CVRFs and/or metabolic syndrome and/or diabetes mellitus and/or endorgan damage (see 3.3.3)
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 350
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 226

•?Pretreatment with Telmisartan.
•?Myocardial infarction within the last 6 months.
•?Previous stroke or hemodynamically relevant stenosis of carotic arteria (> 70%).
•?Previous cardial or peripheral bypass surgery within the last 6 months.
•?PAD stadium III – IV n.F.
•?Chronic heart failure NYHA III- IV.
•?Instable angina.
•?Known intolerance to angiotensin receptor blockers, diuretics or dihydropyridine calcium cannel blocker.

发起方